IVM的新起点:利用pre-IVM使卵母细胞获得发育能力
本综述聚焦于双相IVM(尤其是pre-IVM)的进展。通过从微刺激患者的小窦卵泡中收集未成熟卵母细胞,经约24小时pre-IVM培养后再行IVM。基于C型利钠肽的CAPA-IVM已在临床前人体安全性和有效性试验中显示,其健康活产率与传统IVF无差异。
要点
- 双相IVM包括pre-IVM和IVM,旨在体外继续卵母细胞发育。
- CAPA-IVM作为首个临床测试的双相IVM系统,已显示良好临床结果。
- CAPA-IVM的健康活产率与传统IVF无差异。
核心结论
- 基于C型利钠肽的pre-IVM(CAPA-IVM)已在临床前人体安全性和有效性试验中显示,其健康活产率与传统IVF无差异。
- CAPA-IVM作为首个临床测试的双相IVM系统,其良好临床结果重新激发了人们对IVM作为替代、低干预、低成本、安全、患者友好型ART方法的兴趣,尤其对PCOS患者。
- 同样的新方法正用于癌症患者的生育力保存,并有望用于社会性卵母细胞冷冻。
研究设计与样本
- 本文为叙述性综述,通过PubMed和Web of Science检索同行评议的原创论文和综述。
- 检索关键词包括:oocyte IVM、pre-IVM、biphasic IVM、CAPA-IVM、hCG-triggered/primed IVM、natural cycle IVF/M、ex-vivo IVM、OTO-IVM、oocyte maturation、meiotic competence、oocyte developmental competence、oocyte capacitation、follicle size、cumulus cell (CC)、granulosa cell、COC、gap-junction communication、trans-zonal process、cAMP and IVM、cGMP and IVM、CNP and IVM、EGF-like peptide and IVM、minimal stimulation ART、PCOS。
- 文献包含25年的动物研究,涉及各种pre-IVM和双相IVM程序。
- CAPA-IVM已进行临床前人体安全性和有效性试验。
主要发现
- 标准IVM使用小窦卵泡中的卵母细胞时临床结果欠佳,而pre-IVM旨在在IVM前于体外继续卵母细胞发育。
- Pre-IVM通过引起卵母细胞卵丘细胞的深刻细胞变化来实现这一目标,这些细胞在pre-IVM阶段继续满足卵母细胞的发育需求。
- CAPA-IVM的健康活产率与传统IVF无差异。
临床怎么用
- 双相IVM涉及从微刺激患者/动物(未进行hCG预处理)的小窦卵泡中收集未成熟卵母细胞,并在先进培养系统中进行约24小时的pre-IVM预培养,随后进行常规IVM,再行常规IVF程序。
- 如果安全有效,这种新程序可能对人类ART实践产生重大影响。
- CAPA-IVM已在临床前人体安全性和有效性试验中显示,健康活产率与传统IVF无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: While oocyte IVM is practiced sporadically it has not achieved widespread clinical practice globally. However, recently there have been some seminal advances in our understanding of basic aspects of oocyte biology and ovulation from animal studies that have led to novel approaches to IVM. A significant recent advance in IVM technology is the use of biphasic IVM approaches. These involve the collection of immature oocytes from small antral follicles from minimally stimulated patients/animals (without hCG-priming) and an ∼24 h pre-culture of oocytes in an advanced culture system ('pre-IVM') prior to IVM, followed by routine IVF procedures. If safe and efficacious, this novel procedure may stand to make a significant impact on human ART practices. OBJECTIVE AND RATIONALE: The objectives of this review are to examine the major scientific advances in ovarian biology with a unique focus on the development of pre-IVM methodologies, to provide an insight into biphasic IVM procedures, and to report on outcomes from animal and clinical human data, including safety data. The potential future impact of biphasic IVM on ART practice is discussed. SEARCH METHODS: Peer review original and review articles were selected from PubMed and Web of Science searches for this narrative review. Searches were performed using the following keywords: oocyte IVM, pre-IVM, biphasic IVM, CAPA-IVM, hCG-triggered/primed IVM, natural cycle IVF/M, ex-vivo IVM, OTO-IVM, oocyte maturation, meiotic competence, oocyte developmental competence, oocyte capacitation, follicle size, cumulus cell (CC), granulosa cell, COC, gap-junction communication, trans-zonal process, cAMP and IVM, cGMP and IVM, CNP and IVM, EGF-like peptide and IVM, minimal stimulation ART, PCOS. OUTCOMES: Minimizing gonadotrophin use means IVM oocytes will be collected from small antral (pre-dominant) follicles containing oocytes that are still developing. Standard IVM yields suboptimal clinical outcomes using such oocytes, whereas pre-IVM aims to continue the oocyte's development ex vivo, prior to IVM. Pre-IVM achieves this by eliciting profound cellular changes in the oocyte's CCs, which continue to meet the oocyte's developmental needs during the pre-IVM phase. The literature contains 25 years of animal research on various pre-IVM and biphasic IVM procedures, which serves as a large knowledge base for new approaches to human IVM. A pre-IVM procedure based on c-type natriuretic peptide (named 'capacitation-IVM' (CAPA-IVM)) has undergone pre-clinical human safety and efficacy trials and its adoption into clinical practice resulted in healthy live birth rates not different from conventional IVF. WIDER IMPLICATIONS: Over many decades, improvements in clinical IVM have been gradual and incremental but there has likely been a turning of the tide in the past few years, with landmark discoveries in animal oocyte biology finally making their way into clinical practice leading to improved outcomes for patients. Demonstration of favorable clinical results with CAPA-IVM, as the first clinically tested biphasic IVM system, has led to renewed interest in IVM as an alternative, low-intervention, low-cost, safe, patient-friendly ART approach, and especially for patients with PCOS. The same new approach is being used as part of fertility preservation in patients with cancer and holds promise for social oocyte freezing.
引用
- Gilchrist RB, Ho TM, De Vos M, et al. A fresh start for IVM: capacitating the oocyte for development using pre-IVM. Hum Reprod Update. 2024. PMID: 37639630. doi:10.1093/humupd/dmad023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。